[Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].

Abstract

In order to assess the mortality and toxicity of the Hyper-CVAD protocol used as first-line treatment of acute lymphoblastic leukemia, a retrospective cohort study was performed in patients less than 40 years of age from March to September 2011 treated with Hyper-CVAD regimen. Mortality and toxicity was compared with the results of patients treated with the institutional HGMLAL07 regimen between 2009-2012. 18 patients were included; the median age was 26 years old. Complete remissions (67.7% versus 81.9%) as well as one-year (40% versus 62%) and 2 year survival rates (18% versus 34%) were lower with the Hyper-CVAD regimen. By selecting only patients younger than 35 years, the effectiveness of Hyper-CVAD was also lower. In our experience and because of its high cost and toxicity, the Hyper-CVAD regimen should be limited to patients with relapsed or refractory leukemia.

• Authors: Christian Omar Ramos-Peñafiel, Álvaro Cabrera-García, Etta Rozen-Fuller, Guadalupe González-León, Carolina Balderas, Juan Julio Kassack-Ipiña, Humberto Castellanos-Sinco, Carlos Martínez-Murillo, Efreen Montaño-Figueroa, Adolfo Martínez-Tovar, Irma Olarte-Carrillo, Adrián Santoyo-Sánchez, Juan Collazo-Jaloma
• Journal: Revista peruana de medicina experimental y salud publica (Rev Peru Med Exp Salud Publica) 2014 Jul-Sep Vol. 31 Issue 3 Pg. 525-9 ISSN: 1726-4642 [Electronic] Peru
• Vernacular Title: Comparación del Hyper-CVAD con un régimen institucional en el tratamiento de la leucemia linfoblástica aguda del adulto en un hospital de México.
• PMID: 25418653 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Vincristine
• Dexamethasone
• Doxorubicin
• Cyclophosphamide

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cohort Studies
• Cyclophosphamide (therapeutic use)
• Dexamethasone (therapeutic use)
• Doxorubicin (therapeutic use)
• Female
• Hospitals
• Humans
• Male
• Mexico
• Middle Aged
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
• Retrospective Studies
• Vincristine (therapeutic use)
• Young Adult